Reimbursement Options in Canada
PrFIRAZYR® (icatibant acetate) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older with C1-esterase inhibitor deficiency.
FIRAZYR is supplied through a controlled distribution program that is accessed by patients and pharmacies. Patients or a caregiver should be trained in subcutaneous injection techniques under the guidance of a healthcare professional before they can administer FIRAZYR.
Both public and private reimbursement options for adult patients
Provincial and territorial funding (restrictions apply) in all provinces†,‡
- Reimbursement criteria for each province and territory are listed on their provincial drug formulary or exceptional access program.
- Covered on most private plans.
Prompt replacement doses
- If a replacement dose is required, it can be obtained as soon as the next day (if ordered before 2:30 p.m.), delivered directly to the patient’s home.
OnePath® reimbursement assistance
Once a patient is enrolled, the OnePath® Patient Support Program can assist in seeking reimbursement.
- All enrolled patients are eligible for up to 2 bridging doses while their reimbursement application is pending.
- If a patient reaches their annual coverage limit, Takeda will support the patient to explore all alternative reimbursement options and provide bridging doses, if applicable, until their new insurance cycle begins again.
- If reimbursement is delayed, patients may be considered for additional doses.
Reimbursement questions?
Contact the OnePath® Patient Support Program for assistance.
Phone: 1-844-MY1-PATH (1-844-691-7284)Monday through Friday, 8 a.m. to 8 p.m. EST
Fax: 1-844-951-7284
Email: support@onepathprogram.ca
Consult the product monograph at https://www.takeda.com/en-ca/firazyrpm for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling 1-800-268-2772.
Want to find out more about TAKHZYRO reimbursement?
Click Here- Each province and territory has specific coverage criteria. Contact OnePath® for more details concerning the reimbursement process.
- RAMQ is the Official Mark of the Régie de l’assurance maladie du Québec. RAMQ conditions for the coverage of FIRAZYR: For treatment of acute attacks of HAE with C1-esterase inhibitor deficiency in adults whose diagnosis of HAE (type I or type II) was confirmed by an antigen dosage or a functional dosage of the C1-esterase inhibitor below the lower limit of normal and having suffered at least one medically-confirmed acute attack of HAE. Authorizations will be given for a maximum of twelve syringes of icatibant per 12-month period.1
- Régie de l’assurance maladie du Québec (RAMQ). List of Medications. Last Updated on March 2, 2022. Available at https://ramqinter.prod.acquia-sites.com/sites/default/files/documents/liste_med_2022-03-02_en.pdf